Aspen Grove Capital LLC Has $925,000 Holdings in VanEck Biotech ETF $BBH

Aspen Grove Capital LLC decreased its stake in VanEck Biotech ETF (NASDAQ:BBH) by 33.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,919 shares of the company’s stock after selling 2,519 shares during the quarter. Aspen Grove Capital LLC’s holdings in VanEck Biotech ETF were worth $925,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its stake in VanEck Biotech ETF by 40,463.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after acquiring an additional 492,843 shares during the last quarter. Ascent Advisors LLC bought a new position in shares of VanEck Biotech ETF during the first quarter worth $11,178,000. Raymond James Financial Inc. grew its holdings in shares of VanEck Biotech ETF by 245.9% in the 2nd quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock valued at $10,414,000 after buying an additional 48,297 shares during the period. LPL Financial LLC grew its holdings in shares of VanEck Biotech ETF by 63.5% in the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock valued at $6,021,000 after buying an additional 12,351 shares during the period. Finally, Bank of America Corp DE increased its position in shares of VanEck Biotech ETF by 17.7% in the 2nd quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock valued at $8,042,000 after buying an additional 7,898 shares in the last quarter. 32.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other VanEck Biotech ETF news, major shareholder Sardar Biglari sold 11,000 shares of VanEck Biotech ETF stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $16.71, for a total value of $183,810.00. Following the transaction, the insider owned 3,538,961 shares of the company’s stock, valued at approximately $59,136,038.31. The trade was a 0.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 21,493 shares of company stock worth $359,145.

VanEck Biotech ETF Stock Up 1.4%

Shares of VanEck Biotech ETF stock opened at $204.03 on Friday. VanEck Biotech ETF has a 12 month low of $156.45 and a 12 month high of $212.54. The stock’s fifty day simple moving average is $194.35 and its 200 day simple moving average is $192.32.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.